|  |  |  | **Trimester** | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  | **T1** | | **T2** | | **T3** | |
|  |  |  | **Exposed** | | | | | |
| Variable name | Variable level | Estimate name | Unexposed | Exposed | Unexposed | Exposed | Unexposed | Exposed |
| Number records | - | N | 2,199 | 2,201 | 3,501 | 3,462 | 2,821 | 2,858 |
| Age | - | Median [Q25 - Q75] | 32.00 [27.00 - 36.00] | 32.00 [27.00 - 36.00] | 33.00 [29.00 - 36.00] | 33.00 [29.00 - 36.00] | 33.00 [28.00 - 36.00] | 33.00 [29.00 - 36.00] |
| Age group | 12 to 24 | N (%) | 300 (13.6%) | 290 (13.2%) | 337 (9.6%) | 338 (9.8%) | 275 (9.7%) | 270 (9.4%) |
|  | 25 to 39 | N (%) | 1,745 (79.4%) | 1,754 (79.7%) | 2,835 (81.0%) | 2,805 (81.0%) | 2,278 (80.8%) | 2,320 (81.2%) |
|  | 40 to 55 | N (%) | 154 (7.0%) | 157 (7.1%) | 329 (9.4%) | 319 (9.2%) | 268 (9.5%) | 268 (9.4%) |
| Vaccine brand | Moderna | N (%) | 519 (23.6%) | 514 (23.4%) | 657 (18.8%) | 645 (18.6%) | 507 (18.0%) | 524 (18.3%) |
|  | Pfizer | N (%) | 1,680 (76.4%) | 1,687 (76.6%) | 2,844 (81.2%) | 2,817 (81.4%) | 2,314 (82.0%) | 2,334 (81.7%) |
| Trimester | Trimester 1 | N (%) | 2,199 (100.0%) | 2,201 (100.0%) | - | - | - | - |
|  | Trimester 2 | N (%) | - | - | 3,501 (100.0%) | 3,462 (100.0%) | - | - |
|  | Trimester 3 | N (%) | - | - | - | - | 2,821 (100.0%) | 2,858 (100.0%) |
| Number visits prior year | - | Median [Q25 - Q75] | 11.00 [4.00 - 21.00] | 20.00 [8.00 - 38.00] | 17.00 [9.00 - 28.00] | 32.00 [18.00 - 52.00] | 22.00 [13.00 - 35.00] | 42.00 [26.00 - 64.00] |
| Number prior pregnancies | - | Median [Q25 - Q75] | 1.00 [1.00 - 1.00] | 2.00 [2.00 - 2.00] | 1.00 [1.00 - 1.00] | 2.00 [2.00 - 2.00] | 1.00 [1.00 - 1.00] | 2.00 [2.00 - 2.00] |
| Conditions any time prior | Anemia | N (%) | 551 (25.1%) | 485 (22.0%) | 801 (22.9%) | 744 (21.5%) | 778 (27.6%) | 678 (23.7%) |
|  | Heart conditions | N (%) | 39 (1.8%) | 48 (2.2%) | 75 (2.1%) | 95 (2.7%) | 51 (1.8%) | 64 (2.2%) |
|  | Eclampsia preeclampsia | N (%) | 20 (0.9%) | 21 (1.0%) | 44 (1.3%) | 34 (1.0%) | 40 (1.4%) | 39 (1.4%) |
|  | Asthma | N (%) | 121 (5.5%) | 110 (5.0%) | 200 (5.7%) | 229 (6.6%) | 152 (5.4%) | 184 (6.4%) |
|  | Pneumonia | N (%) | 60 (2.7%) | 77 (3.5%) | 99 (2.8%) | 124 (3.6%) | 88 (3.1%) | 83 (2.9%) |
|  | Hypothyroidism | N (%) | 174 (7.9%) | 167 (7.6%) | 270 (7.7%) | 302 (8.7%) | 222 (7.9%) | 284 (9.9%) |
|  | Depressive disorder | N (%) | 106 (4.8%) | 129 (5.9%) | 197 (5.6%) | 203 (5.9%) | 155 (5.5%) | 161 (5.6%) |
|  | Gestational diabetes | N (%) | 83 (3.8%) | 77 (3.5%) | 181 (5.2%) | 169 (4.9%) | 239 (8.5%) | 255 (8.9%) |
|  | Chronic hypertension | N (%) | 46 (2.1%) | 43 (2.0%) | 87 (2.5%) | 87 (2.5%) | 74 (2.6%) | 71 (2.5%) |
|  | Anxiety disorder | N (%) | 576 (26.2%) | 600 (27.3%) | 974 (27.8%) | 960 (27.7%) | 778 (27.6%) | 788 (27.6%) |
|  | Chronic obstructive lung disease | N (%) | <5 (<5%) | <5 (<5%) | 0 (0.0%) | 6 (0.2%) | <5 (<5%) | <5 (<5%) |
| Drugs prior 180 days | Propulsives | N (%) | 85 (3.9%) | 100 (4.5%) | 167 (4.8%) | 140 (4.0%) | 89 (3.2%) | 102 (3.6%) |
|  | Progestogens | N (%) | 111 (5.0%) | 84 (3.8%) | 213 (6.1%) | 252 (7.3%) | 151 (5.4%) | 121 (4.2%) |
|  | Antimycotics systemic | N (%) | 13 (0.6%) | 14 (0.6%) | 17 (0.5%) | 21 (0.6%) | 7 (0.2%) | 11 (0.4%) |
|  | Estrogens | N (%) | 200 (9.1%) | 202 (9.2%) | 259 (7.4%) | 252 (7.3%) | 161 (5.7%) | 149 (5.2%) |
|  | Antithrombotics | N (%) | 61 (2.8%) | 42 (1.9%) | 185 (5.3%) | 147 (4.2%) | 267 (9.5%) | 194 (6.8%) |
|  | Antihistamines systemic | N (%) | 261 (11.9%) | 261 (11.9%) | 574 (16.4%) | 619 (17.9%) | 421 (14.9%) | 465 (16.3%) |
|  | Antidepressants | N (%) | 102 (4.6%) | 152 (6.9%) | 165 (4.7%) | 169 (4.9%) | 109 (3.9%) | 140 (4.9%) |
|  | Immunoglobulins | N (%) | 5 (0.2%) | 9 (0.4%) | 58 (1.7%) | 67 (1.9%) | 299 (10.6%) | 259 (9.1%) |
|  | Analgesics and antipyretics | N (%) | 613 (27.9%) | 617 (28.0%) | 1,229 (35.1%) | 1,234 (35.6%) | 1,080 (38.3%) | 1,064 (37.2%) |
|  | Antiinflammatory antirehumatic | N (%) | 542 (24.6%) | 567 (25.8%) | 542 (15.5%) | 523 (15.1%) | 189 (6.7%) | 200 (7.0%) |
|  | Antiepileptics | N (%) | 37 (1.7%) | 56 (2.5%) | 67 (1.9%) | 56 (1.6%) | 19 (0.7%) | 28 (1.0%) |
|  | Antibacterials systemic | N (%) | 428 (19.5%) | 461 (20.9%) | 866 (24.7%) | 854 (24.7%) | 706 (25.0%) | 676 (23.7%) |